|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-7-4
|
|
pubmed:abstractText |
Papillary cancer is the most common neoplasm of the thyroid. The mainstay of treatment is thyroidectomy, but most patients are additionally treated with radioactive iodine (RAI). Its utility is controversial. This study seeks to determine whether RAI use affects patient outcome and to identify specific cohorts of patients that benefit from its use.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0022-4790
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2007 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17567872-Carcinoma, Papillary,
pubmed-meshheading:17567872-Carcinoma, Papillary, Follicular,
pubmed-meshheading:17567872-Cohort Studies,
pubmed-meshheading:17567872-Humans,
pubmed-meshheading:17567872-Iodine Radioisotopes,
pubmed-meshheading:17567872-Lymph Nodes,
pubmed-meshheading:17567872-Lymphatic Metastasis,
pubmed-meshheading:17567872-Multivariate Analysis,
pubmed-meshheading:17567872-Prognosis,
pubmed-meshheading:17567872-SEER Program,
pubmed-meshheading:17567872-Survival Analysis,
pubmed-meshheading:17567872-Thyroid Neoplasms,
pubmed-meshheading:17567872-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
|
|
pubmed:affiliation |
Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California 91010, USA.
|
|
pubmed:publicationType |
Journal Article
|
